Cure My Disease

Don't miss your cure!

 Log in / Sign up

Machine Learning-Based phenotyping of IBS patients using multidimensional Patient-Reported outcomes

NCT ID NCT07809646

NEW Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 09, 2026

Summary

The purpose of this study is to identify distinct subgroups (phenotypes) of Irritable Bowel Syndrome (IBS) patients. While traditional IBS classification relies mainly on bowel habits, this research uses a multidimensional questionnaire to capture clinical symptoms, psychological factors, diet triggers, sleep quality, and digital behaviors. By applying advanced machine learning algorithms to these patient-reported outcomes, the study aims to uncover hidden patterns that can help customize future treatments and improve patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A convenience sample of adult patients with a physician-confirmed diagnosis of Irritable Bowel Syndrome (IBS) recruited from online health communities, clinical networks, and social media platforms. The population includes individuals across various demographic backgrounds, IBS subtypes, and symptom severity levels, who are capable of completing a digital questionnaire regarding their clinical and lifestyle characteristics.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants aged 18 years or older. Formal physician-confirmed diagnosis of Irritable Bowel Syndrome (IBS). Ability to access and complete the digital multidimensional questionnaire. Willingness to provide digital informed consent. Exclusion Criteria: Presence of organic gastrointestinal diseases (e.g., Inflammatory Bowel Disease, celiac disease, or colorectal cancer). Presence of alarm/red flag symptoms (e.g., nocturnal symptoms waking the patient). Incomplete or inconsistent questionnaire responses.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IBS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.